BAX BAXTER INTERNATIONAL INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 10456 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.3%
TTM net income YoY-112.0%
TTM EPS YoY-115.2%
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—
Margins
Gross margin30.1%
Operating margin-1.9%
Net margin-6.2%
FCF margin—
EBITDA margin3.8%
Returns
ROE-10.5%
ROA-3.6%
ROIC (approx.)-3.5%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets66.6%
Debt / equity0.00x
Current ratio1.79x
Interest coverage-0.75x
Cash quality & payout
Operating cash flow / net income-2.27x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.98B | $2.96B | $2.70B | $2.97B | $2.83B | $2.81B | $2.62B | $2.75B |
| Cost of revenue | $1.98B | $1.93B | $1.81B | $2.40B | $1.89B | $1.82B | $1.76B | $1.79B |
| Gross profit | $994.00M | $1.03B | $891.00M | $577.00M | $950.00M | $991.00M | $861.00M | $959.00M |
| R&D expense | $125.00M | $129.00M | $139.00M | $126.00M | $118.00M | $134.00M | $140.00M | $211.00M |
| SG&A expense | $730.00M | $735.00M | $728.00M | $761.00M | $708.00M | $718.00M | $703.00M | $761.00M |
| Operating income | $225.00M | $217.00M | $66.00M | -$729.00M | $172.00M | $191.00M | $58.00M | -$435.00M |
| Interest expense | -$13.00M | -$13.00M | -$12.00M | $331.00M | -$10.00M | -$14.00M | -$17.00M | $465.00M |
| Pretax income | $417.00M | $158.00M | -$6.00M | -$756.00M | $121.00M | $133.00M | -$3.00M | -$521.00M |
| Income tax | $119.00M | $23.00M | $11.00M | $279.00M | $172.00M | $11.00M | -$67.00M | -$33.00M |
| Net income | $294.00M | $126.00M | -$15.00M | -$1.13B | -$46.00M | $91.00M | $126.00M | -$512.00M |
| EBITDA | $319.00M | $311.00M | $303.00M | -$489.00M | $262.00M | $297.00M | $305.00M | -$190.00M |
| EPS (basic) | 0.57 | 0.24 | -0.03 | — | -0.09 | 0.18 | 0.25 | -1.00 |
| EPS (diluted) | 0.57 | 0.24 | -0.03 | — | -0.09 | 0.18 | 0.25 | -1.00 |
| Dividends declared per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.17 | 0.17 | 0.17 | 0.17 |
| Weighted avg. shares (diluted) | 520.00M | 518.00M | 515.00M | — | 514.00M | 514.00M | 514.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.98B | $2.15B | $2.02B | $1.97B | $1.73B | $1.69B | $2.29B | $1.76B |
| Receivables | $1.78B | $1.86B | $1.70B | $1.86B | $1.78B | $1.77B | $1.65B | $1.68B |
| Inventory | $2.30B | $2.26B | $2.32B | $2.23B | $2.46B | $2.38B | $2.17B | $2.05B |
| Current assets | $6.83B | $6.99B | $6.85B | $6.87B | $6.93B | $6.75B | $7.04B | $8.85B |
| PP&E, net | $2.87B | $2.91B | $2.91B | $2.91B | $2.81B | $2.80B | $2.72B | $2.87B |
| Goodwill | $4.87B | $4.89B | $4.90B | $4.93B | $5.40B | $5.39B | $5.34B | $5.28B |
| Intangibles | $3.93B | $4.07B | $4.22B | $4.37B | $4.80B | $4.95B | $5.08B | $5.22B |
| Total assets | $19.41B | $19.79B | $19.85B | $20.05B | $21.07B | $21.05B | $21.30B | $25.78B |
| Current liabilities | $3.81B | $3.59B | $3.69B | $2.97B | $3.77B | $2.94B | $3.48B | $6.51B |
| Short-term debt | $0 | $0 | $0 | $1.00M | $4.00M | $6.00M | $11.00M | $2.13B |
| Long-term debt | — | — | — | $9.47B | — | — | — | $10.37B |
| Total debt | — | — | — | $9.47B | — | — | — | $12.50B |
| Total liabilities | $12.94B | $13.61B | $13.83B | $13.95B | $13.85B | $13.75B | $14.25B | $18.76B |
| Shareholders' equity | $6.50B | $6.21B | $6.04B | $6.13B | $7.24B | $7.32B | $7.08B | $6.96B |
| Net debt | — | — | — | $7.51B | — | — | — | $10.74B |
| Cash flow statement | ||||||||
| Operating cash flow | $558.00M | $285.00M | $213.00M | $584.00M | $237.00M | $217.00M | -$193.00M | $488.00M |
| Investing cash flow | -$110.00M | -$117.00M | -$133.00M | -$198.00M | -$111.00M | -$115.00M | $3.27B | -$205.00M |
| Financing cash flow | -$620.00M | -$31.00M | -$11.00M | -$147.00M | -$81.00M | -$762.00M | -$3.23B | $141.00M |
| Depreciation & amortization | $94.00M | $94.00M | $237.00M | $240.00M | $90.00M | $106.00M | $247.00M | $245.00M |
| Stock-based compensation | $30.00M | $33.00M | $10.00M | $37.00M | $35.00M | $35.00M | $10.00M | $39.00M |
| Dividends paid | $5.00M | $5.00M | $5.00M | $87.00M | $87.00M | $87.00M | $87.00M | $147.00M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.